دورية أكاديمية
أعرض في EDS

Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD).

التفاصيل البيبلوغرافية
العنوان: Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD).
المؤلفون: Parameswaran M; Radiology, Massachusetts General Hospital, Boston, USA., Hasan HA; School of Medicine, Hashemite University, Zarqa, JOR., Sadeque J; Internal Medicine, Al Mostaqbal Hospital, Jeddah, SAU., Jhaveri S; Internal Medicine, Smt. Nathiba Hargovandas Lakhmichand Municipal Medical College, Ahmedabad, IND., Avanthika C; Medicine and Surgery, Karnataka Institute of Medical Sciences, Hubli, IND., Arisoyin AE; Internal Medicine, College of Medicine, University of Lagos, Lagos, NGA., Dhanani MB; Internal Medicine, Southwestern University School of Medicine, Cebu City, PHL., Rath SM; Medicine, Srirama Chandra Bhanja Medical College and Hospital, Cuttack, IND.
المصدر: Cureus [Cureus] 2021 Dec 28; Vol. 13 (12), pp. e20776. Date of Electronic Publication: 2021 Dec 28 (Print Publication: 2021).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Non-alcoholic fatty liver disease (NAFLD) refers to a spectrum of diseases involving the deposition of fat in the hepatocytes of people with little to no alcohol consumption. NAFLD is associated with hypertension, diabetes, obesity, etc. As their prevalence increases, the propensity and severity of NAFLD might increase. As per the recently developed multi-hit hypothesis, factors like oxidative stress, genetic predisposition, lipotoxicity, and insulin resistance have been found to play a key role in the development of NAFLD and its associated complications. This article focuses on NAFLD, its pathophysiology, risk factors, and the various genetic and epigenetic factors involved in its development along with possible treatment modalities. We conducted an all-language literature search on Medline, Cochrane, Embase, and Google Scholar until October 2021. The following search strings and Medical Subject Heading (MeSH) terms were used: "NAFLD," "NASH," "Fibrosis," and "Insulin Resistance." We explored the literature on NAFLD for its epidemiology, pathophysiology, the role of various genes, and how they influence the disease and associated complications about the disease and its hepatic and extrahepatic complications. With its rapidly increasing prevalence rates across the world and serious complications like NASH and hepatocellular carcinoma, NAFLD is becoming a major public health issue and more research is needed to formulate better screening tools and treatment protocols.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2021, Parameswaran et al.)
References: Diseases. 2018 Sep 24;6(4):. (PMID: 30249972)
Annu Rev Pathol. 2010;5:145-71. (PMID: 20078219)
J Hepatol. 2010 Aug;53(2):372-84. (PMID: 20494470)
World J Gastroenterol. 2016 Nov 21;22(43):9488-9505. (PMID: 27920470)
Science. 2004 Oct 15;306(5695):457-61. (PMID: 15486293)
JHEP Rep. 2021 May 01;3(4):100301. (PMID: 34113839)
Trends Endocrinol Metab. 2017 Apr;28(4):250-260. (PMID: 27986466)
Cell Metab. 2018 Jan 9;27(1):22-41. (PMID: 28867301)
World J Gastroenterol. 2016 Nov 28;22(44):9844-9852. (PMID: 27956809)
Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40. (PMID: 24768810)
Physiol Rev. 2018 Jul 1;98(3):1371-1415. (PMID: 29767564)
JHEP Rep. 2020 Oct 09;2(6):100192. (PMID: 33163950)
Med Sci Monit. 2020 Mar 19;26:e921887. (PMID: 32191680)
Nat Commun. 2014 Jun 30;5:4309. (PMID: 24978903)
J Hepatol. 2011 Jan;54(1):142-52. (PMID: 20888662)
J Hepatol. 2019 Mar;70(3):531-544. (PMID: 30414863)
Clin Liver Dis. 2018 Feb;22(1):11-21. (PMID: 29128051)
Nat Rev Endocrinol. 2018 Feb;14(2):88-98. (PMID: 29219149)
J Hepatol. 2018 Feb;68(2):268-279. (PMID: 29122391)
Obesity (Silver Spring). 2020 Oct;28(10):1843-1852. (PMID: 32893456)
World J Hepatol. 2019 Feb 27;11(2):138-149. (PMID: 30820265)
World J Gastroenterol. 2014 Jul 14;20(26):8341-50. (PMID: 25024593)
Mayo Clin Proc. 1980 Jul;55(7):434-8. (PMID: 7382552)
Clin Gastroenterol Hepatol. 2009 Nov;7(11):1224-9, 1229.e1-2. (PMID: 19559819)
Semin Liver Dis. 2008 Nov;28(4):339-50. (PMID: 18956290)
PLoS One. 2014 Aug 20;9(8):e105192. (PMID: 25141008)
PLoS Genet. 2011 Mar;7(3):e1001324. (PMID: 21423719)
Hepatology. 2011 Jun;53(6):1883-94. (PMID: 21381068)
Trop Doct. 2018 Apr;48(2):107-112. (PMID: 29145775)
Gastroenterology. 2016 May;150(5):1219-1230.e6. (PMID: 26850495)
Clin Mol Hepatol. 2017 Mar;23(1):1-12. (PMID: 28268262)
Gastroenterology. 2001 Apr;120(5):1183-92. (PMID: 11266382)
Hepatology. 2016 Jul;64(1):73-84. (PMID: 26707365)
Eur J Nutr. 2019 Aug;58(5):1759-1769. (PMID: 29761318)
Am J Med. 1991 Sep 30;91(3C):31S-38S. (PMID: 1928209)
J Hepatol. 2016 Sep;65(3):589-600. (PMID: 27212244)
Sci Rep. 2017 Jul 3;7(1):4492. (PMID: 28674415)
Clin Med (Lond). 2011 Apr;11(2):176-8. (PMID: 21526706)
Science. 2008 Dec 5;322(5907):1539-43. (PMID: 19056984)
JHEP Rep. 2019 Jul 19;1(4):312-328. (PMID: 32039382)
N Engl J Med. 2018 Mar 22;378(12):1096-1106. (PMID: 29562163)
World J Gastroenterol. 2014 Nov 14;20(42):15532-8. (PMID: 25400437)
J Hepatol. 2014 Jul;61(1):75-81. (PMID: 24607626)
Gastroenterology. 2018 Oct;155(4):1140-1153. (PMID: 29990488)
Medicina (Kaunas). 2019 Jan 24;55(2):. (PMID: 30682878)
Nat Rev Gastroenterol Hepatol. 2013 May;10(5):307-18. (PMID: 23458891)
Cell Mol Life Sci. 2019 Jan;76(1):99-128. (PMID: 30343320)
Diabetes Metab Syndr Obes. 2014 Dec 04;7:587-91. (PMID: 25506234)
FEBS Open Bio. 2014 May 24;4:522-32. (PMID: 25003023)
J Clin Endocrinol Metab. 2016 Mar;101(3):945-52. (PMID: 26672639)
Antioxid Redox Signal. 2017 Apr 1;26(10):519-541. (PMID: 27452109)
Hepatology. 2011 Oct;54(4):1208-16. (PMID: 21688282)
J Hepatol. 2016 Dec;65(6):1263-1265. (PMID: 27520876)
Biochem Biophys Res Commun. 2018 Oct 7;504(3):608-616. (PMID: 29778532)
Semin Liver Dis. 2015 Aug;35(3):236-49. (PMID: 26378641)
Atherosclerosis. 2013 Oct;230(2):258-67. (PMID: 24075754)
Gastroenterology. 2015 Aug;149(2):389-97.e10. (PMID: 25935633)
PLoS Biol. 2007 May;5(5):e110. (PMID: 17472436)
Dig Liver Dis. 2017 May;49(5):471-483. (PMID: 28215516)
Nat Rev Gastroenterol Hepatol. 2011 Jul 12;8(8):425-6. (PMID: 21750513)
Hepatology. 2018 Jan;67(1):328-357. (PMID: 28714183)
Dig Dis Sci. 2012 Jul;57(7):1773-81. (PMID: 22419057)
Ann N Y Acad Sci. 2013 Apr;1281:106-22. (PMID: 23363012)
J Hepatol. 2012 Feb;56(2):448-54. (PMID: 21756849)
Front Med (Lausanne). 2015 Jan 21;2:1. (PMID: 25654080)
JAMA. 2015 Jun 9;313(22):2263-73. (PMID: 26057287)
Endocrine. 2015 Aug;49(3):711-6. (PMID: 25358448)
Clin Liver Dis (Hoboken). 2020 Sep 04;16(2):66-72. (PMID: 32922753)
Biochem J. 2002 Dec 1;368(Pt 2):545-53. (PMID: 12180906)
Nature. 2018 Mar 29;555(7698):673-677. (PMID: 29562231)
Front Pharmacol. 2020 Dec 03;11:603926. (PMID: 33343375)
Metabolism. 2016 Aug;65(8):1038-48. (PMID: 26823198)
Hepatology. 2008 Dec;48(6):1810-20. (PMID: 19030170)
Gastroenterology. 2015 Mar;148(3):547-55. (PMID: 25461851)
J Hepatol. 2021 Jan;74(1):20-30. (PMID: 32882372)
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):32-42. (PMID: 27729660)
Glob Health Epidemiol Genom. 2019 Apr 12;4:e3. (PMID: 31019719)
J Hepatol. 2021 Apr;74(4):775-782. (PMID: 33248170)
Pediatr Res. 2014 Jan;75(1-2):140-7. (PMID: 24192698)
Am J Epidemiol. 2013 Jul 1;178(1):38-45. (PMID: 23703888)
Dig Dis. 2010;28(1):179-85. (PMID: 20460908)
World J Hepatol. 2014 May 27;6(5):274-83. (PMID: 24868321)
Int J Mol Sci. 2021 Apr 24;22(9):. (PMID: 33923295)
Exp Mol Pathol. 2018 Feb;104(1):50-58. (PMID: 29307798)
Gut. 2017 Jun;66(6):1138-1153. (PMID: 28314735)
Curr Opin Organ Transplant. 2018 Apr;23(2):169-174. (PMID: 29356708)
J Bone Miner Res. 2019 Jul;34(7):1254-1263. (PMID: 31074909)
Life Sci. 2021 Nov 15;285:119997. (PMID: 34597608)
Endocrinology. 2020 Oct 1;161(10):. (PMID: 32776116)
Transl Gastroenterol Hepatol. 2020 Apr 05;5:16. (PMID: 32258520)
Cells. 2021 May 31;10(6):. (PMID: 34072832)
Int J Mol Sci. 2019 Dec 19;21(1):. (PMID: 31861664)
World J Gastroenterol. 2011 Aug 7;17(29):3377-89. (PMID: 21876630)
J Clin Exp Hepatol. 2021 Mar-Apr;11(2):219-226. (PMID: 33746447)
J Hepatol. 2017 Jun;66(6):1300-1312. (PMID: 28267621)
World J Gastroenterol. 2016 Mar 14;22(10):3023-30. (PMID: 26973398)
Obes Rev. 2013 May;14(5):417-31. (PMID: 23387384)
Food Chem Toxicol. 2015 Jun;80:298-309. (PMID: 25846498)
Contemp Clin Trials. 2020 Feb;89:105922. (PMID: 31881392)
Nat Genet. 2014 Apr;46(4):352-6. (PMID: 24531328)
Clin Gastroenterol Hepatol. 2014 Mar;12(3):403-4. (PMID: 24262942)
World J Gastroenterol. 2011 Aug 28;17(32):3663-4. (PMID: 21990946)
Curr Gastroenterol Rep. 2019 Apr 11;21(4):17. (PMID: 30976932)
Ann Med. 2012 Feb;44(1):29-40. (PMID: 21355790)
Am J Gastroenterol. 2003 Nov;98(11):2485-90. (PMID: 14638353)
J Hepatol. 2015 Aug;63(2):494-502. (PMID: 25776890)
Metabolism. 2016 Aug;65(8):1017-25. (PMID: 26997539)
Int J Mol Sci. 2014 May 14;15(5):8591-638. (PMID: 24830559)
Int J Mol Med. 2005 Aug;16(2):237-43. (PMID: 16012755)
J Zhejiang Univ Sci B. 2008 Aug;9(8):616-22. (PMID: 18763311)
World J Gastroenterol. 2014 Jul 28;20(28):9338-44. (PMID: 25071328)
Dig Dis Sci. 2017 Oct;62(10):2915-2922. (PMID: 28744836)
J Biol Chem. 2010 Feb 26;285(9):6706-15. (PMID: 20034933)
J Hepatol. 2012 Jun;56(6):1356-62. (PMID: 22314430)
Nat Genet. 2008 Dec;40(12):1461-5. (PMID: 18820647)
Gastroenterology. 2021 Apr;160(5):1634-1646.e7. (PMID: 33347879)
Mod Pathol. 2019 Jul;32(7):997-1007. (PMID: 30809000)
Free Radic Biol Med. 2020 May 20;152:116-141. (PMID: 32156524)
Adv Ther. 2017 Jun;34(6):1291-1326. (PMID: 28526997)
Front Cell Dev Biol. 2021 Sep 09;9:736677. (PMID: 34568346)
PLoS Med. 2014 Jul 22;11(7):e1001680. (PMID: 25050550)
Gastroenterology. 1998 Apr;114(4):764-74. (PMID: 9516397)
Nat Rev Gastroenterol Hepatol. 2020 May;17(5):260. (PMID: 32235911)
Eur J Clin Invest. 2020 Oct;50(10):e13338. (PMID: 32589264)
Lancet. 2016 Feb 13;387(10019):679-690. (PMID: 26608256)
J Hepatol. 2017 Jan;66(1):123-131. (PMID: 27599824)
Am J Kidney Dis. 2014 Oct;64(4):638-52. (PMID: 25085644)
Gut. 2013 Sep;62(9):1356-63. (PMID: 22879518)
J Hepatol. 2015 May;62(5):1148-55. (PMID: 25477264)
Nat Commun. 2017 Jun 13;8:15691. (PMID: 28608850)
Hepatology. 2012 Jun;55(6):2005-23. (PMID: 22488764)
Mitochondrion. 2006 Feb;6(1):1-28. (PMID: 16406828)
J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10. (PMID: 16540768)
Liver Int. 2014 Oct;34(9):1402-13. (PMID: 24650018)
Gut. 2004 May;53(5):750-5. (PMID: 15082596)
World J Hepatol. 2020 Oct 27;12(10):792-806. (PMID: 33200017)
Hepatology. 2020 Mar;71(3):808-819. (PMID: 31675427)
Mol Cell Biol. 2015 Dec;35(24):4121-34. (PMID: 26438600)
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. (PMID: 21623852)
Hepatology. 2012 Sep;56(3):943-51. (PMID: 22505194)
Liver Int. 2009 Jan;29(1):113-9. (PMID: 18384521)
JAMA. 2011 Oct 12;306(14):1549-56. (PMID: 21990298)
Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):656-65. (PMID: 24080776)
Clin Epigenetics. 2021 Aug 5;13(1):152. (PMID: 34353365)
Hepatology. 2010 May;51(5):1820-32. (PMID: 20432259)
J Hepatol. 2013 Mar;58(3):593-608. (PMID: 23419824)
Ann Hepatol. 2010 Oct-Dec;9(4):402-9. (PMID: 21057159)
Int J Mol Sci. 2021 Jul 19;22(14):. (PMID: 34299321)
J Pediatr Gastroenterol Nutr. 2012 May;54(5):700-13. (PMID: 22395188)
World J Gastroenterol. 2018 Jul 21;24(27):2974-2983. (PMID: 30038464)
Nat Med. 2018 Jul;24(7):908-922. (PMID: 29967350)
Eur Med J Hepatol. 2018;6(1):100-109. (PMID: 29930864)
Gastroenterology. 2003 Aug;125(2):437-43. (PMID: 12891546)
Genes Dev. 2010 Nov 15;24(22):2463-79. (PMID: 21078816)
Hepatol Res. 2015 Oct;45(10):E53-61. (PMID: 25429984)
World J Gastroenterol. 2018 Nov 21;24(43):4835-4845. (PMID: 30487694)
Mol Syst Biol. 2010;6:347. (PMID: 20160708)
Arch Pharm Res. 2019 Nov;42(11):935-946. (PMID: 31571145)
Curr Opin Lipidol. 2014 Jun;25(3):213-20. (PMID: 24785962)
Mol Aspects Med. 2017 Apr;54:78-88. (PMID: 27889327)
فهرسة مساهمة: Keywords: demographics; disease progression; human genetics and epigenetics; long-term prognosis; mitochondrial senescence; nonalcoholic fatty liver disease (nafld); treatment choices
تواريخ الأحداث: Date Created: 20220203 Latest Revision: 20220204
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8794413
DOI: 10.7759/cureus.20776
PMID: 35111461
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.20776